A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

Sponsor
University Hospital, Bordeaux
Study ID
NCT01245660
Phase
EARLY_PHASE1
Status
Terminated

Conditions

  • Bladder Carcinoma
  • Cystectomy
  • Infiltrative Bladder Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LAPATINIB — DRUG
    Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.

Study Details

Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.

Key Dates

Start date
Jan 31, 2011
Status verified
Jan 2013
Primary completion
Oct 31, 2011
Completion
Oct 31, 2011

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Experimental: Patient

Primary Outcome Measure

Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib. [ Time Frame: At surgery (day 21-27) ]

Related Studies